

7. Elišák M. Ocrelizumab – dlouhodobé údaje o účinnosti a bezpečnosti v reálné klinické praxi u pacientů s relaps remittentní roztroušenou sklerózou. *Neurol. praxi.* 2022;23(3):233-237.

8. Engmann NJ, Sheinson D, Bawa K, et al. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data. *Journal of Managed Care & Specialty Pharmacy.* 2021;27(5):639-649. <https://doi.org/10.18553/JMCP.2021.20413>.

9. Grillo-López AJ. Rituximab (Rituxan/MabThera): the first decade (1993-2003). *Expert Review of Anticancer Therapy.* 2003;3(6):767-779. <https://doi.org/10.1586/14737140.3.6.767>.

10. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. *New England Journal of Medicine.* 2017;376(3):221-234. <https://doi.org/10.1056/NEJMJA1601277>.

11. Hauser SL, Kappos L, Montalban X, et al. Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis. *Neurology.* 2021;97(16):E1546-E1559. <https://doi.org/10.1212/WNL.00000000000012700>.

12. Hellwig K, Oreja-Guevara C, Vukusic S, et al. Pregnancy and Infant Outcomes in Women Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of the Largest Available Outcomes Database [P061]. 9th JointECTRIMS ACTRIMS Meeting. 2023.

13. Hrnčiarova T, Drahota J, Spelman T, et al. Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries. *Multiple Sclerosis and Related Disorders.* 2023;76. <https://doi.org/10.1016/j.msard.2023.104803>.

14. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial. *The Lancet.* 2011;378(9805):1779-1787. [https://doi.org/10.1016/S0140-6736\(11\)61649-8](https://doi.org/10.1016/S0140-6736(11)61649-8).

15. Kappos L, Traboulsee A, Li DKB, et al. Ocrelizumab expo-

sure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension. *Journal of Neurology.* 2023. <https://doi.org/10.1007/S00415-023-11943-4>.

16. Kim T, Brinker A, Croteau D, et al. Immune-mediated colitis associated with ocrelizumab: A new safety risk. *Multiple Sclerosis (Houndmills, Basingstoke, England).* 2023;29(10):1275-1281. <https://doi.org/10.1177/13524585231195854>.

17. Kingwell E, Bajdik C, Phillips N, et al. Cancer risk in multiple sclerosis: findings from British Columbia, Canada. *Brain A Journal of Neurology.* 2012;135(Pt 10):2973-2979. <https://doi.org/10.1093/BRAIN/AWS148>.

18. Krejský J. Biologika anti CD20 modulaci zralých B lymfocytů účinně tlumí poškozující zánět u nemocných s roztroušenou sklerózou. Na způsobu podání biologika záleží? *Remedia.* 2023.

19. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. *The New England Journal of Medicine.* 2017;376(3):30-31. <https://doi.org/10.1056/NEJMJA1606468>.

20. Nielsen NM, Rostgaard K, Rasmussen S, et al. Cancer risk among patients with multiple sclerosis: a population-based register study. *International Journal of Cancer.* 2006;118(4):979-984. <https://doi.org/10.1002/IJC.21437>.

21. Ochs J, Nissimov N, Torke S, et al. Proinflammatory CD20+ T cells contribute to CNS-directed autoimmunity. *Science Translational Medicine.* 2022;14(638). <https://doi.org/10.1126/SCITRANSLMED.ABI4632>.

22. Oksbjerg NR, Nielsen SD, Blinksberg M, et al. Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases. *Mult Scler Relat Disord.* 2021;52:102988. <https://doi.org/10.1016/j.msard.2021.102988>.

23. Simonsen CS, Flemmen HØ, Broch L, et al. Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian

Population-Based Registry. *Frontiers in Neurology.* 2021;12. <https://doi.org/10.3389/FNEUR.2021.693017>.

24. Spelman T, Magyari M, Piehl F, et al. Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies. *JAMA Neurology.* 2021;78(10):1197-1204. <https://doi.org/10.1001/JAMANEURO.2021.2738>.

25. Stastna D, Drahota J, Lauer M, et al. The Czech National MS Registry (ReMuS): Data trends in multiple sclerosis patients whose first disease-modifying therapies were initiated from 2013 to 2021. *Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechia.* 2023. <https://doi.org/10.5507/BP.2023.015>.

26. Štastná D, Horáková D. Dekáda terapie cílené na B lymfocyty aneb adherence a perzistence ocrelizumabu na jedničku. *Multiple Sclerosis NEWS.* 2023;9(2):23-28.

27. Stastna D, Menkyova I, Drahota J, et al. Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia. *Mult Scler Relat Disord.* 2021;54:103-104. <https://doi.org/10.1016/j.msard.2021.103104>.

28. Stastna D, Menkyova I, Horakova D. Okrelizumab již od první ataky roztroušené sklerózy – milník v úhradových kritériích. *Neurol. praxi.* 2022;23(4):312-316. <https://doi.org/10.36290/neu.2022.030>.

29. Štastná D, Menkyová I, Horáková D. Vysoce účinná terapie již od první ataky – důležitý posun v léčbě roztroušené sklerózy? *Neurol. praxi.* 2023;24(1):40-44. <https://doi.org/10.36290/NEU.2022.068>.

30. Weber M, Kappos L, Hauser S, et al. The Patient Impact of 10 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long-Term Data from the Phase III OPERA and ORATORIO Studies [Poster P302]. 9th JointECTRIMS ACTRIMS Meeting. 2023.

ON-LINE KURZ

Úskalí klasické imunosupresivní léčby

OBSAH KURZU

- ▶ **Současná a nová léčba myasthenie gravis: praxe a výzvy**
MUDr. Stanislav Vohánka, CSc., MBA, MUDr. Magda Horáková
- ▶ **Eculizumab v terapii thymom-asociované myasthenie**
MUDr. Magda Horáková, MUDr. Viktória Kokošová, prof. MUDr. Josef Bednařík, CSc., MUDr. Stanislav Vohánka, CSc., MBA
- ▶ **Kazuistika k diskuzi** – MUDr. Michaela Týblová, Ph.D.
- ▶ **Farmakorezistentní myastenik s thymomem** – MUDr. Jana Junkerová
- ▶ **Novinky v léčbě myasthenia gravis** – MUDr. Michaela Týblová, Ph.D.

ODBORNÝ GARANT:

MUDr. Stanislav Vohánka, CSc., MBA

POŘADATEL: Společnost SOLEN, s. r. o.,
ve spolupráci s Neurologickou klinikou LF MU
a FN Brno, Neuromuskulárním centrem ERN

POČET
KREDITŮ **2**

Registrace
ZDARMA

TERMÍN
listopad 2023
až říjen 2024
dostupný na
online.solen.cz

